Razpis: Preclinical Drug Discovery
Funding for promising preclinical drug discovery and biomarker development programmes relevant to Alzheimer's disease, other dementias and cognitive ageing.
Financer: Alzheimer's Drug Discovery Foundation
Največja vrednost projekta: 150.000,00 EUR/leto; ADDF dopušča možnost večletnih projektov in dodatnih financiranj
Upravičenost kandidatov: javne in zasebne pravne osebe, profitne in neprofitne organizacije, vključno z akademskimi ustanovami in biotehnološkimi podjetji, ne glede na lokacijo
Rok za prijavo: 17. 11. 2017
Prijava: preko spletne strani ADDF
Founded in 1998 by co-chairmen Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation (ADDF) provides funding to leading scientists who are conducting the most promising, innovative Alzheimer's drug research worldwide.
The ADDF aims to plug the translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer's disease, other dementias and cognitive ageing.
The ADDF's Preclinical Drug Discovery scheme works through three mechanisms:
- Academic Program: seeks to create and support innovative translational programs in academic medical centres and universities.
- Biotechnology Development Program: supports qualified scientific projects in existing, private, early-stage biotechnology companies. The ADDF will provide support for qualified projects in more advanced companies if a clear need for non-profit funding to support the project can be demonstrated and justified. Funding is typically made as a program-related investment.
- Biotechnology Founders Technology Transfer Program: supports academic programs that are eligible for technology transfer and the start-up of new biotechnology companies. Up to 35% of funds from these awards may be employed for expenses related to company formation, such as administrative, legal, patent and third-party vendor costs.
Terms and Conditions
2015 Preclinical Research Funding Priorities:
- Drug Discovery: Target validation, high throughput screening, medicinal chemistry-including hit to lead development and lead optimisation, in vitro and in vivo efficacy studies, ADME, toxicology, pharmacokinetics and pharmacodynamics, and in vivo proof-of-concept with lead compounds and biologics.
- Biomarker Development: Development of blood, CSF, and imaging biomarkers to accelerate clinical trials, allow for accurate and early diagnosis, and to track disease progression.
With regards to potential drug targets:
- The ADDF is interested in novel targets and therapeutic approaches for Alzheimer's disease, related dementias and cognitive ageing. These areas include, but are not limited to: Energy utilisation/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury, the blood-brain barrier interface, and translatable biomarkers.
- The ADDF has limited interest in funding anti-amyloid approaches, including anti-amyloid aggregation programs, a beta vaccine development and beta or gamma-secretase inhibition programs. The ADDF also has limited interest in funding cholinesterase inhibitor programmes.
Programme areas of particular interest include:
- Repurposing: Testing drugs approved for other indications in Alzheimer's disease preclinical models. Proposals should be hypothesis driven and drugs chosen for testing should target a mechanism of action(s) common to both diseases.
- New chemical compounds for Alzheimer's disease: Requires BOTH a medicinal chemist and a biologist as co-PIs/collaborators. The programme should focus on new scaffolds, generation of tool compounds, improving CNS-focused chemical libraries, and optimizing novel lead compounds.
- Preclinical proof-of-concept: Testing of novel lead compounds in animal models. Study design should be clearly outlined along the lines of an exploratory or therapeutic animal study as described in the ADDF's recent publication, Accelerating Drug Discovery for Alzheimer's Disease: Best Practices for Preclinical Animal Studies. Whenever possible, studies should include pharmacokinetics (PK) and pharmacodynamics (PD) testing, an a priori hypothesis and primary and secondary outcomes measures, and a statistical design plan including power analysis.